References of "Brue, T"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailMRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment.
Eroukhmanoff, J.; Tejedor, I.; Potorac, Iulia ULg et al

in European Journal of Endocrinology (2017), 176(3), 323-328

OBJECTIVE: Both antitumor and antisecretory efficacies of dopamine agonists (DA) make them the first-line treatment of macroprolactinomas. However, there is no guideline for MRI follow-up once prolactin ... [more ▼]

OBJECTIVE: Both antitumor and antisecretory efficacies of dopamine agonists (DA) make them the first-line treatment of macroprolactinomas. However, there is no guideline for MRI follow-up once prolactin is controlled. The aim of our study was to determine whether a regular MRI follow-up was necessary in patients with long-term normal prolactin levels under DA. PATIENTS AND METHODS: We conducted a retrospective multicenter study (Marseille, Paris La Pitie Salpetriere and Nancy, France; Liege, Belgium) including patients with macroprolactinomas (largest diameter: >10 mm and baseline prolactin level: >100 ng/mL) treated by dopamine agonists, and regularly followed (pituitary MRI and prolactin levels) during at least 48 months once normal prolactin level was obtained. RESULTS: In total, 115 patients were included (63 men and 52 women; mean age at diagnosis: 36.3 years). Mean baseline prolactin level was 2224 +/- 6839 ng/mL. No significant increase of tumor volume was observed during the follow-up. Of the 21 patients (18%) who presented asymptomatic hemorrhagic changes of the macroprolactinoma on MRI, 2 had a tumor increase (2 and 7 mm in the largest size). Both were treated by cabergoline (1 mg/week) with normal prolactin levels obtained for 6 and 24 months. For both patients, no further growth was observed on MRI during follow-up at the same dose of cabergoline. CONCLUSION: No significant increase of tumor size was observed in our patients with controlled prolactin levels on DA. MRI follow-up thus appears unnecessary in patients with biologically controlled macroprolactinomas. [less ▲]

Detailed reference viewed: 26 (2 ULg)
Full Text
See detailFaut-il suivre par IRM hypophysaire les patients porteurs de macroprolactinome dont l'hypersécrétion est contrôlée médicalement ?
Eroukhmanoff, J; Tejedor, I; Potorac, Iulia ULg et al

in Annales d'Endocrinologie : 33ème congrès de la Société Française d'Endocrinologie (2016, October)

Detailed reference viewed: 14 (1 ULg)
Full Text
Peer Reviewed
See detailGPR101 mutations are not a frequent cause of congenital isolated growth hormone deficiency
Castinetti, F; Daly, Adrian ULg; Stratakis, CA et al

in Hormone & Metabolic Research (2016)

Detailed reference viewed: 33 (10 ULg)
Full Text
See detailHow T2-weighted signal intensity of GH-secreting adenomas correlates wit response to primary somatostatin analogue therapy in acromegaly
Potorac, Iulia ULg; PETROSSIANS, Patrick ULg; Daly, Adrian ULg et al

in Abstract book - 25th meeting of the Belgian Endocrine Society (2015, October)

Detailed reference viewed: 30 (6 ULg)
Full Text
See detailDo T2-hypointense GH-secreting pituitary adenomas behave differently under somatostatin analogues as primary therapy in acromegaly ?
Potorac, Iulia ULg; PETROSSIANS, Patrick ULg; Daly, Adrian ULg et al

in The International Journal of The Romania Society of Endocrinology - Abstract book (2015, June)

Detailed reference viewed: 31 (3 ULg)
Full Text
See detailIntérêt du signal T2 des adénomes hypophysaires à GH traités par analogues de la somatostatine - premiers résultats de l'étude IRMA#2
Potorac, Iulia ULg; PETROSSIANS, Patrick ULg; Daly, Adrian ULg et al

in Abstract book - Annales d'Endocrinologie : 31ème Congrès de la Société Françaose d'Endocrinologie, Lyon 5-8 novembre 2014 (2014, October)

Detailed reference viewed: 37 (10 ULg)
Full Text
See detailCorrelations of the High Resolution MRI aspect of GH-secreting pituitary adenomas prior to treatment
Potorac, Iulia ULg; PETROSSIANS, Patrick ULg; Schillo, F et al

in Abstract book - Symposium "Perspectives in Endocrinology" Congresses Highlights 2013:ECE Copenhagen, ENDO SF, SFE Paris (2014, February)

Detailed reference viewed: 34 (7 ULg)
Full Text
See detailHypopituitarism in pituitary gigantism (results of an international study)
Rostomyan, L; Daly, Adrian ULg; Shah, N et al

in Abstract book - Symposium "Perspectives in Endocrinology" Congresses Highlights 2013:ECE Copenhagen, ENDO SF, SFE Paris (2014, February)

Detailed reference viewed: 43 (6 ULg)
Full Text
See detailHypopituitarism in pituitary gigantism (results of an international study)
Rostomyan, Liliya ULg; Daly, Adrian ULg; Shah, NS et al

in The 3rd ENEA Workshop : Hypopituitarism - Abstract book (2013, December)

Detailed reference viewed: 29 (4 ULg)
Full Text
Peer Reviewed
See detailCorrelations of the High Resolution MRI aspect of GH-secreting pituitary adenomas prior to treatment
Potorac, Iulia ULg; PETROSSIANS, Patrick ULg; Schillo, F et al

in 23rd meeting of the Belgian Endocrine Society - Abstract book (2013, October 19)

Detailed reference viewed: 40 (5 ULg)
Full Text
Peer Reviewed
See detailLe gigantisme : Les résultats d'une étude clinique et génétique internationale
Rostomyan, Liliya ULg; Daly, Adrian ULg; Lila, A et al

in Annales d'Endocrinologie (2013, October), 74

Detailed reference viewed: 40 (8 ULg)
Full Text
Peer Reviewed
See detailCorrélations significatives de l'aspect en IRM haute résolution des adénomes hypophysairesà GH avant traitement
Potorac, Iulia ULg; PETROSSIANS, Patrick ULg; Schillo, F et al

in Annales d'Endocrinologie (2013, October), 74

Detailed reference viewed: 78 (16 ULg)
Full Text
See detailErythropoiesis in acromegaly : effect of GH or IGF-1 ? Data from the LAS (Liege Acromegaly Survey)
PETROSSIANS, Patrick ULg; Zacharieva, S; Chanson, P et al

in Journal für Klinische Endokrinologie und Stoffwechsel (2012, September), 5(3), 45

Detailed reference viewed: 28 (4 ULg)
Full Text
See detailGH or IGF-1 : which one is raising blood glucose ? Hints from the LAS (Liege Acromegaly Survey)
PETROSSIANS, Patrick ULg; Zacharieva, S; Chanson, P et al

in Journal of Klinische Endokrinologie und Stoffwechsel (2012, September), 5(3),

Detailed reference viewed: 23 (2 ULg)
Full Text
See detailAge, GH and tumor size : the triangular relation in acromegaly. Data from the LAS (Liege Acromegaly Survey)
PETROSSIANS, Patrick ULg; Zacharieva, S; Chanson, P et al

in Journal für Klinische Endokrinologie und Stoffwechsel (2012, September), 5(3), 43

Detailed reference viewed: 42 (7 ULg)
Full Text
See detailAging of the newly diagnosed acromegalic patients : data frome the LAS (Liege Acromegaly Survey)
PETROSSIANS, Patrick ULg; Zacharieva, S; Chanson, P et al

in Journal für Klinische Endokrinologie und Stoffwechsel (2012, September), 5(3), 33

Detailed reference viewed: 25 (3 ULg)
Full Text
See detailCaracteristicas de prolactinomas resisitentes a dosis estandar de cabergolina : un estudio multicentrico en 92 pacientes
Beckers, Albert ULg; Jaffrain-Réa, ML; VROONEN, Laurent ULg et al

in Abstract book - 54 Congreso Sociedad Espanola de Endocrinologia y nutrition (2012, May 23)

Detailed reference viewed: 30 (0 ULg)
Full Text
Peer Reviewed
See detailClinical characterization of cabergoline resistant prolactinomas : a multicenter experience on 92 patients
VROONEN, Laurent ULg; Jaffrain Rea, ML; PETROSSIANS, Patrick ULg et al

in Annales d'Endocrinologie (2012, April), 73(2), 153

Detailed reference viewed: 42 (5 ULg)